PATIENT REPORTED OUTCOMES-CORE SHARED RESOURCE The Patient Reported Outcomes-Core Shared Resource (PRO-core) was developed in response to a growing number of cancer center investigators who require methodological consulting related to survey development, use, and analysis, as well as use of a customizable electronic data capture tool for collecting information directly from patients and other stakeholders. PRO Core provides a software platform and scientific consultation to investigators conducting PRO research. This includes clinical trials of new drugs, interventions with symptom and quality of life endpoints, and studies of the integration of PRO assessment into clinical care. Dr. Bennett is the faculty director and an Associate Professor of Health Policy and Management. She contributed as an investigator to the development and validation of the NCI Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). In fiscal year 2019, the SR was used by 27 faculty, 67% of whom were LCCC members. Importantly, the SR supports highly sophisticated methodology and is a national leader in Patient Reported Outcomes. These skills and methods allow the SR to support external cancer collaborators at multi-site trial locations such as Duke Cancer Institute, Emory University, Georgetown, and Moffit. PRO is requesting $111,249 for this SR which is approximately 39% of its fiscal year 2020 Operating budget. PRO Core has been a successful SR as demonstrated by the following metrics. PRO Core studies are supported by 11 NIH grants (5 from NCI, including 1 K award) and 3 Patient-Centered Outcomes Research Institute (PCORI) contracts. Studies are also supported by Genentech, the Breast Cancer Research Foundation, and pilot awards from the Alliance for Clinical Trials in Oncology cooperative group. PRO Core is supporting a growing portfolio of: 1) studies evaluating the implementation of PRO assessment in oncology care, and 2) studies collecting both PRO data and wearable / activity tracker (e.g. Garmin, Fitbit) data. PRO Core has developed technical capability and expertise in these areas, and the LCCC is now known for substantial scientific leadership in these two areas. In addition, PRO Core is supporting studies that evaluate the comparative effectiveness of new treatments and a new registry that tracks opioid need and use among post-operative patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089834
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468

Showing the most recent 10 out of 1525 publications